Patricia L. Gordon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Patricia L. Gordon has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Amie Thompson
Greenwood Genet Ctr, Greenwood, SC 29646 USA
1 shared publication - Brenda S. DiBoscio
Division of Human Genetics/Metabolism, Children’s Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA
1 shared publication - Caitlin Menello
Section of Biochemical Genetics, Division of Genetics, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA
1 shared publication - Can Ficicioglu
Section of Biochemical Genetics, Division of Genetics, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA
1 shared publication - Caroline Eggerding
Cooper Univ Hosp, Camden, NJ 08103 USA
1 shared publication - Damara Ortiz
UPMC Children's Hospital of Pittsburgh, 4401 Penn Avenue, Pittsburgh, PA 15224, USA
1 shared publication
Latest Publications
- Open Access
- 13 November 2020
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 6 (4) , 89
Newborn Screening for Pompe Disease: Pennsylvania Experience
Pennsylvania started newborn screening for Pompe disease in February 2016. Between February 2016 and December 2019, 531,139 newborns were screened. Alpha-Glucosidase (GAA) enzyme activity is measured by flow-injection tandem mass spectrometry (FIA/MS/MS) and full sequencing of the GAA gene is performed as a second-tier test in all newborns with low GAA enzyme activity [<2.10 micromole/L/h]. A total of 115 newborns had low GAA enzyme activity and abnormal genetic testing and were referred to metabolic centers. Two newborns were diagnosed with Infantile Onset Pompe Disease (IOPD), and 31 newborns were confirmed to have Late Onset Pompe Disease (LOPD). The incidence of IOPD + LOPD was 1:16,095. A total of 30 patients were compound heterozygous for one pathogenic and one variant of unknown significance (VUS) mutation or two VUS mutations and were defined as suspected LOPD. The incidence of IOPD + LOPD + suspected LOPD was 1: 8431 in PA. We also found 35 carriers, 15 pseudodeficiency carriers, and 2 false positive newborns.
- 13 November 2020
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 6 (4) , 89
Open AccessNewborn Screening for Pompe Disease: Pennsylvania Experience
Pennsylvania started newborn screening for Pompe disease in February 2016. Between February 2016 and December 2019, 531,139 newborns were screened. Alpha-Glucosidase (GAA) enzyme activity is measured by flow-injection tandem mass spectrometry (FIA/MS/MS) and full sequencing of the GAA gene is performed as a second-tier test in all newborns with low GAA enzyme activity [<2.10 micromole/L/h]. A total of 115 newborns had low GAA enzyme activity and abnormal genetic testing and were referred to metabolic centers. Two newborns were diagnosed with Infantile Onset Pompe Disease (IOPD), and 31 newborns were confirmed to have Late Onset Pompe Disease (LOPD). The incidence of IOPD + LOPD was 1:16,095. A total of 30 patients were compound heterozygous for one pathogenic and one variant of unknown significance (VUS) mutation or two VUS mutations and were defined as suspected LOPD. The incidence of IOPD + LOPD + suspected LOPD was 1: 8431 in PA. We also found 35 carriers, 15 pseudodeficiency carriers, and 2 false positive newborns.
- Open Access
- 1 June 2020
- Published by Elsevier in Molecular Genetics and Metabolism Reports
- Vol. 23, 100571
Strategies to engage lost to follow-up patients with phenylketonuria in the United States: Best practice recommendations
- 1 June 2020
- Published by Elsevier in Molecular Genetics and Metabolism Reports
- Vol. 23, 100571
Open AccessStrategies to engage lost to follow-up patients with phenylketonuria in the United States: Best practice recommendations